Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 4, 2006, Pages 507-511

  Formann, E ^a   Steindl Munda, P ^a   Hofer, H ^a   Jessner, W ^a   Bergholz, U ^a   Gurguta, C ^a   Ferenci, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; TREATMENT OUTCOME; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; INTERFERON-ALPHA; INTERFERONS; MALE; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33644917972     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02785.x     Document Type: Article

References (35)

1. Strader DB Wright T Thomas DL Seeff LB Diagnosis, management, and treatment of hepatitis C Hepatology 2004 39 1147 71
2. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus Statements 2002 19 1 46 Review
3. Manns MP McHutchison JG Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001 358 958 65
4. Fried MW Shiffman ML Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 2002 347 975 82
5. Hadziyannis SJ Sette Jr H. Morgan TR et al Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 2004 140 346 55
6. Nishiguchi S Kuroki T Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 1995 346 1051 5
7. Yoshida H Shiratori Y Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy Ann Intern Med 1999 13 174 81
8. Yoshida H Tateishi R Arakawa Y et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C Gut 2004 53 425 30
9. Shiratori Y Imazeki F Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann Intern Med 2000 132 517 24
10. Saracco G Rosina F Abate ML et al. Long-term followup of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b Hepatology 1993 18 1300 5
11. Reichard O Glaumann H Fryden A et al. Two year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment Hepatology 1995 21 918 22
12. Marcellin P Boyer N Gervais A et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann Intern Med 1997 127 875 81
13. Ferenci P Brunner H Nachbaur K et al. Combination of interferon induction therapy and ribavirin in chronic hepatitis C Hepatology 2001 34 1006 11
14. Ferenci P Stauber R Steindl-Munda P et al. Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. Austrian Hepatitis Study Group q8 Eur J Gastroenterol Hepatol 2001 13 699 705
15. Formann E Jessner W Bennett L Ferenci P Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1 J Viral Hepat 2003 10 271 6
16. Jessner W Gschwantler M Steindl-Munda P et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study Lancet 2001 358 1241 2
17. Ferenci P Formann E Laferl H et al Randomized, controlled, double-blind, placebo-controlled study of peginterferon alfa-2a plus ribavirin with or without amantadine in patients with chronic hepatitis C genotype 1 infection J Hepatology doi: 10.1016/j.jhep.2005.09.015
18. Veldt BJ Saracco G Boyer N et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy Gut 2004 53 1504 8
19. Schvarcz R Glaumann H Reichard O Weiland O Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C J Viral Hepat 1999 6 237 42
20. Larghi A Tagger A Crosignani A et al. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy J Med Virol 1998 55 7 11
21. Shindo M Hamada K Oda Y Okuno T Long-term follow-up study of sustained biochemical responders with interferon therapy Hepatology 2001 33 1299 302
22. Tsuda N Yuki N Mochizuki K et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy J Med Virol 2004 74 406 13
23. Lau DT Kleiner DE Ghany MG Park Y Schmid P Hoofnagle JH 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C Hepatology 1998 28 1121 7
24. Soriano V Maida I Nunez M et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies Antivir Ther 2004 9 987 92
25. Swain M Lai MY Shiffman ML et al Durability of sustained virological response (SVR) after treatment with peginterferon alfa 2A (40 kD) (PEGASYS) alone or in combination with ribavirin (Copegus): results of an ongoing long-term follow-up study Hepatology 2004 40 Suppl. 1 400A; AASLD 2004, Abstract
26. McHutchison JG Poynard T Esteban-Mur R et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin Hepatology 2002 35 688 93
27. Radkowski M Gallegos-Orozco JF Jablonska J et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C Hepatology 2005 41 106 14
28. Pham TN MacParland SA Mulrooney PM Cooksley H Naoumov NV Michalak TI Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C J Virol 2004 78 5867 74
29. Castillo I Pardo M Bartolome J et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown J Infect Dis 2004 189 7 14
30. Castillo I Rodriguez-Inigo E Bartolome J et al. Hepatitis C virus replicates in peripheral blood mononuclear cells of patients with occult hepatitis C virus infection Gut 2005 54 682 5
31. Feld JJ Liang TJ HCV persistence cure is still a four letter word Hepatology 2005 41 23 5
32. Zoulim F New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA J Hepatol 2005 42 302 8
33. Klenerman P Hill A T cells and viral persistence: lessons from diverse infections Nat Immunol 2005 6 873 9
34. Loginov R Hockerstedt K Lautenschlager I Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment Arch Virol 2003 148 1269 74
35. Neary MP Cort S Bayliss MS Ware Jr JE. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients Semin Liver Dis 1999 19 Suppl. 1 77 85